Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Offered by National Institutes of Health; awards $1.5M; applications due November 5, 2027.
Key Facts
- Funder
- National Institutes of Health
- Award amount
- $1.5M
- Deadline
- November 5, 2027
- Geography
- United States
- Categories
- Research
- Status
- Open
About This Grant
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion,...
Full requirements and application instructions: official listing.
Similar Open Grants
Research Centers in Minority Institutions (RCMI) Coordinating Center (U24 - Clinical Trial Optional)
National Institutes of Health
Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
National Institutes of Health
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
National Institutes of Health
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
National Institutes of Health
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
National Institutes of Health
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
National Institutes of Health
BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)
National Institutes of Health
Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
National Institutes of Health